BRKR - Biognosys launches groundbreaking P2 Plasma Enrichment technology for unbiased deep plasma proteomics at ASMS 2024 | Benzinga
- The proprietary P2 Plasma Enrichment method leverages a novel single-well, single particle-type enrichment method to achieve market-leading performance for unbiased, deep mass spectrometry-based plasma proteomics
- P2 now offers excellent quantitation and higher throughput for large-cohort biomarker or drug discovery studies, and clinical, epidemiological or population proteomics research
- P2 Plasma Enrichment is available as a CRO service via Biognosys' TrueDiscovery® platform, or as an in-house method for high-performance mass spectrometry end-users via licensing
- With the optional additional combination of TrueDiscovery® unbiased, deep mass spectrometry proteomics workflows with targeted Alamar NULISA affinity-based ultra-high sensitivity proteomics panels, Biognosys now enables the most quantitative and complete access to the human plasma proteome
ZURICH, Switzerland and NEWTON, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Biognosys, a leader in next-generation proteomics services, software and kits for life sciences research and drug development, today announced the launch of the novel, proprietary P2 Plasma Enrichment method for single-well, single particle-type enrichment with market leading performance and sensible, superior economics. P2-based plasma proteomics can be used for human or for animal-model proteomics studies and clinical research.
This novel P2 plasma proteomics method achieves a proteome coverage of 7,000 proteins in a previously published five-cancer plasma sample set, demonstrating highest reproducibility, unprecedented enrichment of low abundant proteins, and unparalleled throughput on Bruker timsTOF® HT mass spectrometers. The technical features and performance data will be presented at the American Society of Mass Spectrometry (ASMS) Annual Conference in Anaheim, CA on Monday, June 3rd during Biognosys' Breakfast Seminar, "Accelerating Drug Discovery and Development with Biognosys' Next-Generation Proteomics Services," and on Wednesday, June 5th during the WP 084 poster session.
"With our proprietary P2 Plasma Enrichment method, Biognosys can now significantly enhance the depth and throughput in plasma proteomics beyond what existing methods could achieve," explains Dr. Oliver Rinner, CEO and founder of Biognosys. "Most importantly, this advancement comes with ...